571 related articles for article (PubMed ID: 11158089)
1. Comparison of DNA sequencing and a line probe assay for detection of human immunodeficiency virus type 1 drug resistance mutations in patients failing highly active antiretroviral therapy.
Servais J; Lambert C; Fontaine E; Plesséria JM; Robert I; Arendt V; Staub T; Schneider F; Hemmer R; Burtonboy G; Schmit JC
J Clin Microbiol; 2001 Feb; 39(2):454-9. PubMed ID: 11158089
[TBL] [Abstract][Full Text] [Related]
2. Comparative performance evaluation of the HIV-1 LiPA protease and reverse transcriptase resistance assay on clinical isolates.
Tsongalis GJ; Gleeson T; Rodina M; Anamani D; Ross J; Joanisse I; Tanimoto L; Ziermann R
J Clin Virol; 2005 Dec; 34(4):268-71. PubMed ID: 16286050
[TBL] [Abstract][Full Text] [Related]
3. Absence of resistance mutations in antiretroviral-naive patients treated with ritonavir-boosted saquinavir.
Ananworanich J; Hirschel B; Sirivichayakul S; Ubolyam S; Jupimai T; Prasithsirikul W; Chetchotisakd P; Kiertiburanakul S; Munsakul W; Raksakulkarn P; Tansuphasawadikul S; Schutz M; Snowden W; Ruxrungtham K;
Antivir Ther; 2006; 11(5):631-5. PubMed ID: 16964832
[TBL] [Abstract][Full Text] [Related]
4. Longitudinal use of a line probe assay for human immunodeficiency virus type 1 protease predicts phenotypic resistance and clinical progression in patients failing highly active antiretroviral therapy.
Servais J; Lambert C; Plesséria JM; Fontaine E; Robert I; Arendt V; Staub T; Hemmer R; Schneider F; Schmit JC
Antimicrob Agents Chemother; 2002 Jun; 46(6):1928-33. PubMed ID: 12019110
[TBL] [Abstract][Full Text] [Related]
5. [Polymorphism of protease genes in patients infected with HIV-1 and response to therapy including a protease inhibitor].
Mouroux M; Bossi P; Yvon-Groussin A; Delaugerre C; Valantin MA; Tubiana R; Coutellier A; Bonmarchand M; Bricaire F; Katlama C; Agut H; Huraux JM; Calvez V
Pathol Biol (Paris); 1999 May; 47(5):549-52. PubMed ID: 10418038
[TBL] [Abstract][Full Text] [Related]
6. Clinical validation of saquinavir/ritonavir genotypic resistance score in protease-inhibitor-experienced patients.
Marcelin AG; Flandre P; de Mendoza C; Roquebert B; Peytavin G; Valer L; Wirden M; Abbas S; Katlama C; Soriano V; Calvez V
Antivir Ther; 2007; 12(2):247-52. PubMed ID: 17503666
[TBL] [Abstract][Full Text] [Related]
7. Virological response to darunavir/ritonavir-based regimens in antiretroviral-experienced patients (PREDIZISTA study).
Pellegrin I; Wittkop L; Joubert LM; Neau D; Bollens D; Bonarek M; Girard PM; Fleury H; Winters B; Saux MC; Pellegrin JL; Thiébaut R; Breilh D;
Antivir Ther; 2008; 13(2):271-9. PubMed ID: 18505178
[TBL] [Abstract][Full Text] [Related]
8. Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: mutation patterns and baseline correlates.
Mo H; King MS; King K; Molla A; Brun S; Kempf DJ
J Virol; 2005 Mar; 79(6):3329-38. PubMed ID: 15731227
[TBL] [Abstract][Full Text] [Related]
9. Profile of drug resistance mutations among HIV-1-infected Tunisian subjects failing antiretroviral therapy.
Jlizi A; Ben Ammar El Gaaied A; Slim A; Tebourski F; Ben Mamou M; Ben Chaabane T; Letaief-Omezzine A; Chakroun M; Garbouj M; Ben Rejeb S
Arch Virol; 2008; 153(6):1103-8. PubMed ID: 18483694
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of transmitted nucleoside analogue-resistant HIV-1 strains and pre-existing mutations in pol reverse transcriptase and protease region: outcome after treatment in recently infected individuals.
Balotta C; Berlusconi A; Pan A; Violin M; Riva C; Colombo MC; Gori A; Papagno L; Corvasce S; Mazzucchelli R; Facchi G; Velleca R; Saporetti G; Galli M; Rusconi S; Moroni M
Antivir Ther; 2000 Mar; 5(1):7-14. PubMed ID: 10846586
[TBL] [Abstract][Full Text] [Related]
11. Monitoring the emergence of hepatitis B virus polymerase gene variants during lamivudine therapy in human immunodeficiency virus coinfected patients: performance of CLIP sequencing and line probe assay.
Roque-Afonso AM; Férey MP; Mackiewicz V; Fki L; Dussaix E
Antivir Ther; 2003 Dec; 8(6):627-34. PubMed ID: 14760897
[TBL] [Abstract][Full Text] [Related]
12. Human immunodeficiency virus 1 strains resistant to nucleoside inhibitors of reverse transcriptase in isolates from the Czech Republic as monitored by line probe assay and nucleotide sequencing.
Reinis M; Vandasová J; Stanková M; Linka M; Brůcková M
Acta Virol; 2001; 45(5-6):279-86. PubMed ID: 12083326
[TBL] [Abstract][Full Text] [Related]
13. Monitoring resistance to human immunodeficiency virus type 1 protease inhibitors by pyrosequencing.
O'Meara D; Wilbe K; Leitner T; Hejdeman B; Albert J; Lundeberg J
J Clin Microbiol; 2001 Feb; 39(2):464-73. PubMed ID: 11158091
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of genotypic resistance among antiretroviral drug-naive HIV-1-infected patients in Belgium.
Van Vaerenbergh K; Debaisieux L; De Cabooter N; Declercq C; Desmet K; Fransen K; Maes B; Marissens D; Miller K; Muyldermans G; Sprecher S; Stuyver L; Vaira D; Verhofstede C; Zissis G; Van Ranst M; De Clercq E; Desmyter J; Vandamme AM
Antivir Ther; 2001 Mar; 6(1):63-70. PubMed ID: 11417763
[TBL] [Abstract][Full Text] [Related]
15. Persistence of earlier HIV-1 drug resistance mutations at new treatment failure.
Svedhem V; Lindkvist A; Lidman K; Sönnerborg A
J Med Virol; 2002 Dec; 68(4):473-8. PubMed ID: 12376953
[TBL] [Abstract][Full Text] [Related]
16. Impact of HIV type 1 protease, reverse transcriptase, cleavage site, and p6 mutations on the virological response to quadruple therapy with saquinavir, ritonavir, and two nucleoside analogs.
Kaufmann GR; Suzuki K; Cunningham P; Mukaide M; Kondo M; Imai M; Zaunders J; Cooper DA
AIDS Res Hum Retroviruses; 2001 Apr; 17(6):487-97. PubMed ID: 11350662
[TBL] [Abstract][Full Text] [Related]
17. Human immunodeficiency virus type 1 protease cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, ritonavir, and/or saquinavir.
Côté HC; Brumme ZL; Harrigan PR
J Virol; 2001 Jan; 75(2):589-94. PubMed ID: 11134271
[TBL] [Abstract][Full Text] [Related]
18. Clinical cross-resistance between the HIV-1 protease inhibitors saquinavir and indinavir and correlations with genotypic mutations.
Schapiro JM; Winters MA; Lawrence J; Merigan TC
AIDS; 1999 Feb; 13(3):359-65. PubMed ID: 10199226
[TBL] [Abstract][Full Text] [Related]
19. Comparative evaluation of three human immunodeficiency virus genotyping systems: the HIV-GenotypR method, the HIV PRT GeneChip assay, and the HIV-1 RT line probe assay.
Wilson JW; Bean P; Robins T; Graziano F; Persing DH
J Clin Microbiol; 2000 Aug; 38(8):3022-8. PubMed ID: 10921971
[TBL] [Abstract][Full Text] [Related]
20. [Evaluating the therapeutic care of HIV infection in Tunisia].
Jlizi A; Slim A; Benammar Elgaaied A; Ben Rejab S; Ben Chaabane T; Letaief-Omezzine A; Chakroun M; Garbouj M
Tunis Med; 2008 Jun; 86(6):534-9. PubMed ID: 19216443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
